ABBREVIATION |
DEFINITION AND NOTES |
|---|---|
ACA |
Patient Protection and Affordable Care Act |
AFP |
alpha-fetoprotein |
ALT |
alanine aminotransferase |
AMP |
average manufacturer price |
Anti-HBc |
hepatitis B core total antibody |
Anti-HBs |
hepatitis B surface antibody |
Anti-HCV |
HCV antibody |
APRI |
AST-to-platelet ratio index |
AST |
aspartate aminotransferase |
AUC |
area under the curve |
AWP |
average wholesale price |
BCLC |
Barcelona-Clinic liver cancerl |
BCRP |
breast cancer resistance protein |
CBC |
complete blood count |
CDC |
US Centers for Disease Control and Prevention |
CEA |
cost-effectiveness analysis |
CI |
confidence interval |
CTP |
Child-Turcotte-Pugh (see CTP classification table below) |
CYP |
cytochrome P450 enzyme |
DAA |
direct-acting antiviral |
eGFR |
estimated glomerular filtration rate |
ESRD |
end-stage renal disease |
FDA |
US Food and Drug Administration |
HBsAG |
hepatitis B virus surface antigen |
HBV |
hepatitis B virus |
HCC |
hepatocellular carcinoma |
HCV |
hepatitis C virus |
HCV RNA |
hepatitis C virus ribonucleic acid |
HR |
hazard ratio |
ICER |
incremental cost-effectiveness ratio |
IDU |
injection drug use or user |
INR |
international normalized ratio |
MELD |
model for end-stage liver disease |
MOUD |
medication for opioid use disorder |
MSM |
men who have sex with men |
MTCT |
mother-to-child transmission |
NASH |
nonalcoholic steatohepatitis |
NAT |
nucleic acid testing |
NGS |
next generation sequencing |
NIH |
US National Institutes of Health |
NS3 |
HCV nonstructural protein 3 |
NS5A |
HCV nonstructural protein 5A |
OATP |
organic anion-transporting polypeptide |
OR |
odds ratio |
OS |
overall survival |
PBM |
pharmacy benefit manager |
PCR |
polymerase chain reaction |
P-gp |
P-glycoprotein |
POC |
point of care |
PrEP |
preexposure prophylaxis |
PWID |
people who inject drugs |
QALY |
quality-adjusted life-year |
RAS |
resistance-associated substitution |
RBC |
red blood cell(s) |
RBV |
ribavirin |
RGT |
response-guided therapy |
RR |
relative risk |
sAg |
surface antigen |
SSP |
syringe service program |
SOF |
sofosbuvir |
SVR12 (or 24 or 48, etc) |
sustained virologic response at 12 weeks (or at 24 weeks, or at 48 weeks, etc) |
TDF |
tenofovir disoproxil fumarate |
TSH |
thyrotropin (previously thyroid-stimulating hormone) |
ULN |
upper limit of normal |
USPSTF |
US Preventive Services Task Force |
VCTE |
vibration-controlled transient liver elastography |
WAC |
wholesale acquisition costb |
a “List price” for wholesale pharmacies to purchase drugs |
|
Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
CLASS A |
CLASS B |
CLASS C |
|
Total points |
5-6 |
7-9 |
10-15 |
Factor |
1 point |
2 points |
3 points |
Total bilirubin (µmol/L) |
<34 |
34-50 |
>50 |
Serum albumin (g/L) |
>35 |
28-35 |
<28 |
International normalized ratio |
<1.7 |
1.71-2.3 |
>2.3 |
Ascites |
None |
Mild |
Moderate to severe |
Hepatic encephalopathy |
None |
Grade I-II (or suppressed with medication) |
Grade III-IV (or refractory) |
Last Update: January 5, 2025 Last Review: January 15, 2025
